Holen Sie sich die Stockscreener-App
2.71
1.50%
0.04
Vorhandelsmarkt:
2.80
0.09
+3.32%
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield - Yahoo Finance
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer - Bakersfield.com
ImmunityBio (IBRX) Receives Maintained Buy Rating from D. Boral Capital | IBRX Stock News - GuruFocus
FDA grants expanded access to ImmunityBio’s Anktiva for lymphopenia - Yahoo
FDA authorizes ANKTIVA for lymphopenia in cancer patients By Investing.com - Investing.com South Africa
ImmunityBio (IBRX) Gains FDA Nod for Cancer BioShield Platform - GuruFocus
ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva - Seeking Alpha
Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield? Platform, in Patients with Solid Tumors - marketscreener.com
FDA authorizes ANKTIVA for lymphopenia in cancer patients - Investing.com Australia
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Placera.se
Immunitybio Receives FDA Expanded Access Authorization For Landmark Treatment Of Lymphopenia With Anktiva - marketscreener.com
Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, - openPR.com
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio - The Globe and Mail
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
ImmunityBio: BioShield Platform Expands to Middle East and Other Important Updates - TradingView
ImmunityBio: Analyst Reaffirms $30 Price Target and Other Important Updates - TradingView
While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey
ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX S - GuruFocus
ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX Stock News - GuruFocus
Cancer BioShield Platform Comes to Saudi Arabia and the Middle East - Vax-Before-Travel
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - BioSpace
ImmunityBio Signs Agreement to Launch BioShield in Saudi Arabia, Middle East - marketscreener.com
Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East - marketscreener.com
ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding - marketscreener.com
ImmunityBio (IBRX) Expands Cancer Treatment Platform to Middle E - GuruFocus
Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail
ImmunityBio Board Settles Shareholders’ Cancer Therapy Lawsuit - Bloomberg Law News
Why ImmunityBio, Inc. (IBRX) Crashed Today - MSN
Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT - Insider Monkey
Piper Sandler Upgrades ImmunityBio (NASDAQ:IBRX) to Overweight - Defense World
Jim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever” - Insider Monkey
Piper Sandler Upgrades ImmunityBio (IBRX) - Nasdaq
10 Firms Drenched in Red Today - Insider Monkey
Jim Cramer’s Recent Thoughts on These 15 Stocks - Insider Monkey
Piper Sandler raises ImmunityBio stock rating, target to $5 By Investing.com - Investing.com Nigeria
ImmunityBio (IBRX) Upgraded to Overweight by Piper Sandler - GuruFocus
Why ImmunityBio, Inc. (IBRX) Surged Last Week - Insider Monkey
ImmunityBio upgraded to Overweight at Piper Sandler on Anktiva success - Seeking Alpha
ImmunityBio (IBRX) Receives Analyst Upgrade and Price Target Increase | IBRX Stock News - GuruFocus
Piper Sandler raises ImmunityBio stock rating, target to $5 - Investing.com
ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Ca - GuruFocus
ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Cancer Therapies | IBRX Stock News - GuruFocus
Why ImmunityBio’s Stock is on the Rise - TipRanks
ImmunityBio (IBRX) Receives Upgrade from Piper Sandler | IBRX Stock News - GuruFocus
Dimensional Fund Advisors LP Boosts Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal
Mercer Global Advisors Inc. ADV Purchases 8,359 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
ImmunityBio, Inc. (NASDAQ:IBRX) Holdings Decreased by Price T Rowe Associates Inc. MD - Defense World
Biotechs need a new guidebook to parse FDA messaging: a Perspective - BioCentury
Q2 Earnings Forecast for ImmunityBio Issued By HC Wainwright - Defense World
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00 - Yahoo
0.87%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):